Ratings by Truist Securities (Danielle Brill)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | Disc Medicine | IRON | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2026 | BridgeBio Pharma | BBIO | Maintain | (N/A) |
|
Details | ||
| 2/24/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2026 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Hold (N/A) |
|
Details | ||
| 2/20/2026 | Harmony Biosciences Holdings Inc. | HRMY | Downgrade | Hold (Buy) |
34.39 (28.33) |
-17.62% | Details | |
| 2/17/2026 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 2/9/2026 | Immunovant | IMVT | Maintain | Hold (N/A) |
|
Details | ||
| 2/9/2026 | Biogen | BIIB | Maintain | Hold (N/A) |
|
Details | ||
| 1/29/2026 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2026 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2025 | Insmed | INSM | New Coverage | Buy (N/A) |
198.46 (140.13) |
-29.39% | Details | |
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2025 | Jefferson Capital | JCAP | Maintain | Buy (N/A) |
|
Details | ||
| 11/10/2025 | Disc Medicine | IRON | Maintain | Buy (N/A) |
|
Details | ||
| 11/10/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 10/31/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | Disc Medicine | IRON | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2025 | Dianthus Therapeutics | DNTH | New Coverage | Buy (N/A) |
34.42 (65.20) |
89.42% | Details | |
| 10/14/2025 | Upstream Bio | UPB | New Coverage | Buy (N/A) |
20.08 (7.66) |
-61.85% | Details | |
| 10/14/2025 | Immunovant | IMVT | New Coverage | Hold (N/A) |
17.35 (26.66) |
53.66% | Details | |
| 10/2/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | argenx SE | ARGX | New Coverage | Buy (N/A) |
756.39 (717.80) |
-5.1% | Details | |
| 9/10/2025 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 9/2/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2025 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 7/21/2025 | Biogen | BIIB | New Coverage | Hold (N/A) |
124.99 (184.87) |
47.91% | Details | |
| 7/21/2025 | Tectonic Therapeutics Inc. | TECX | New Coverage | Buy (N/A) |
21.91 (35.87) |
63.72% | Details | |
| 7/21/2025 | Centessa Pharmaceuticals | CNTA | New Coverage | Buy (N/A) |
15.69 (25.95) |
65.39% | Details | |
| 7/21/2025 | Disc Medicine | IRON | New Coverage | Buy (N/A) |
57.77 (61.18) |
5.9% | Details | |
| 7/21/2025 | Jefferson Capital | JCAP | New Coverage | Buy (N/A) |
16.70 (21.38) |
28.02% | Details | |
| 7/21/2025 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
132.02 (128.13) |
-2.95% | Details | |
| 7/21/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
29.51 (134.39) |
355.4% | Details | |
| 7/21/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
320.53 (320.66) |
0.04% | Details | |
| 7/21/2025 | BridgeBio Pharma | BBIO | New Coverage | Buy (N/A) |
46.51 (65.36) |
40.53% | Details | |
| 7/21/2025 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Buy (N/A) |
35.20 (28.33) |
-19.52% | Details |
